论文部分内容阅读
为评价Ｃｅｌｕｖｉｓｃ治疗角膜上皮病变的效果，采用前瞻性研究，将３４例５７眼角膜上皮病变患者随机分为Ｃｅｌｕｖｉｓｃ治疗组（１７例２９眼）及ＳｏｌｏｃｏｓｅｒｙＥｙｅ－ｇｅｌ对照组（１７例２８眼），观察两组的治疗效果。结果：经４周的治疗及随访，治疗组２９眼均有效，其中９眼治愈，２０眼好转。对照组有２１眼有效，其中５眼治愈，１６眼好转，无效７眼，均为干眼症患者，且经应用Ｃｅｌｕｖｉｓｃ治疗后好转。在点状角膜炎及角膜上皮缺损组，两组的治愈率与好转率经统计学处理无显著差异（Ｘ２检验，Ｘ２＝１．２０８，Ｐ＞０．２５）。但在泪液分泌不足的干眼症组，治疗组的好转率明显高于对照组（Ｘ２检验，Ｘ２＝９．９７５，Ｐ＜０．００５）。结论：Ｃｅｌｕｖｉｓｃ治疗角膜上皮病变安全、有效，尤其适用于治疗干眼引起的角膜上皮病变。
To evaluate the efficacy of celuvisc in the treatment of corneal epithelial lesions, a prospective study of 34 patients with 57 corneal epithelial lesions were randomly divided into Celuvisc treatment group (17 eyes) and Solocosery Eye-gel control group (17 eyes) The treatment effect of both groups. Results: After 4 weeks of treatment and follow-up, 29 of the treatment group were effective, of which 9 were cured, 20 were improved. In the control group, 21 eyes were effective, of which 5 eyes were cured, 16 eyes improved and 7 eyes were ineffective. All of them were patients with dry eye and were improved after treatment with Celuvisc. In the group of punctate keratitis and corneal epithelial defect, there was no significant difference in the cure rate and improvement rate between the two groups (X2 test, X2 = 1.208, P> 0.25). However, in the dry eye group with insufficient tear secretion, the improvement rate of the treatment group was significantly higher than that of the control group (X2 test, X2 = 9.975, P <0.005). Conclusion: Celuvisc is safe and effective for the treatment of corneal epithelial lesions and is especially suitable for the treatment of corneal epithelial lesions caused by dry eye.